Non-randomized Observational Study to Collate Data Regarding the Safety, Efficacy and Satisfaction of ReX® in the Management of Solid Oral Medications.
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Any Solid Oral Medication
- Sponsor
- Dosentrx Ltd.
- Enrollment
- 1000
- Locations
- 1
- Primary Endpoint
- Treatment duration
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
The goal of this observational study is to evaluate the safety, efficacy and patient satisfaction with the ReX Remote Digital Nurse by patients receiving solid oral medication.
The study will evaluate and monitor use of ReX in respect of:
- treatment duration
- adverse events
- patient adherence and compliance
- engagement with ReX via patient-reported outcomes
Patients participating in the study will receive their normal medication as standard of care via ReX. Progress will be monitored via patients' responses to questions presented on the ReX touch screen.
Detailed Description
The ReX platform is a class 1 FDA device listed under product code NXB Dispenser Solid Medication. It comprises: * Hand-held medication dispenser with touch screen (ReX Remote Digital Nurse). * Disposable cartridge pre-loaded with pills or capsules. The cartridge includes an integral mouthpiece. Patients inhale at the mouthpiece causing pills to be dispensed into the mouth. * Web application (ReX Treatment Manager) which collects data generated by the ReX hand-held dispenser. ReX manages and monitors medication-based therapy by means of: * Reminders to take pills. Reminders are sent to patients and caregivers by email, SMS or via the telephone support team. * Electronic patient recorded outcomes (ePROs) presented to patients via the dispenser touch screen. ePROs include questions, tips and reminders. * Notifications sent by email or SMS in the event of the patient exceeding a pre-defined threshold. In this study, following training, patients will be offered their standard oral medication via the ReX Remote Digital Nurse. They will receive cartridges pre-loaded with medication by the pharmacy. Safety, efficacy and patient satisfaction with the device are monitored over a 24-week period by phone calls and periodic questionnaires. Data collected by the ReX Remote Digital Nurse include: * medication name * prescribed dosage * doses taken per day * pills taken per dose * ePRO responses * missed pill intakes
Investigators
Eligibility Criteria
Inclusion Criteria
- •18 years of age or older.
- •Care team recommends the use of ReX as a standard of care.
- •Patients have 5th grade reading level.
- •Patient was prescribed oral medication.
- •Patient takes medication at home.
Exclusion Criteria
- •Patient has significant physical disability including poor fine motor skills, impaired visual or auditory faculties, mental disorders or other impairment affecting ability to provide Informed Consent or use the ReX dispensing unit effectively.
- •Patient failed to pass the learning module during ReX onboarding flow.
- •Patient is at end stage or terminal illness with anticipated life expectancy of 6 months or less.
Outcomes
Primary Outcomes
Treatment duration
Time Frame: 24 weeks
At least 3 months while using ReX
Patient satisfaction
Time Frame: 24 weeks
At least 3.5 on a scale up to 5
Adverse events
Time Frame: 24 weeks
None related to use of ReX
Patient adherence
Time Frame: 24 weeks
No. of pills taken by patient as a percentage of pills prescribed \>80%
Patient compliance
Time Frame: 24 weeks
No. of pills taken as percentage of pills to be taken in alloted time frame \>70%
Patient engagement
Time Frame: 24 weeks
No. of questions answered as a percentage of questions asked \>70% of ePROs